Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tau PET Substudy of Crenezumab in Preclinical Familial Alzheimer's Disease
NCT03977584Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2019
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of crenezumab in Alzheimer's disease (AD), sponsored by Roche. Started Jun 2019; status: completed.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03977584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03977584.